Unicycive Therapeutics, Inc. (UNCY) stock
UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.70+0.00 (0.00%)
Close on Nov 17, 2026Market cap $103.06MP/E –Yield –
Unicycive Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Unicycive Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.61M, down 21.6% year over year. For fiscal 2025 it was $9.12M, down 54.4% from the year before. The highest annual figure on record is $20.01M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.12M | -54.4% |
| FY2024 | Dec 31, 2024 | $20.01M | +55.1% |
| FY2023 | Dec 31, 2023 | $12.90M | +3.7% |
| FY2022 | Dec 31, 2022 | $12.44M | +104.5% |
| FY2021 | Dec 31, 2021 | $6.08M | +499.0% |
| FY2020 | Dec 31, 2020 | $1.02M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.79M | +59.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.61M | -26.0% |
| Q4 FY2025 | Dec 31, 2025 | $2.25M | -57.5% |
| Q3 FY2025 | Sep 30, 2025 | $2.96M | -2.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.75M | -64.1% |
| Q1 FY2025 | Mar 31, 2025 | $2.17M | -68.1% |
| Q4 FY2024 | Dec 31, 2024 | $5.29M | +24.9% |
| Q3 FY2024 | Sep 30, 2024 | $3.05M | -9.7% |
| Q2 FY2024 | Jun 30, 2024 | $4.87M | +114.7% |
| Q1 FY2024 | Mar 31, 2024 | $6.81M | +124.9% |
| Q4 FY2023 | Dec 31, 2023 | $4.23M | +10.2% |
| Q3 FY2023 | Sep 30, 2023 | $3.37M | -29.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.27M | +21.9% |
| Q1 FY2023 | Mar 31, 2023 | $3.03M | +56.8% |
| Q4 FY2022 | Dec 31, 2022 | $3.84M | +182.1% |
| Q3 FY2022 | Sep 30, 2022 | $4.80M | +27.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.86M | +277.3% |
| Q1 FY2022 | Mar 31, 2022 | $1.93M | +329.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.36M | +256.3% |
| Q3 FY2021 | Sep 30, 2021 | $3.78M | +1142.1% |
| Q2 FY2021 | Jun 30, 2021 | $493.00K | +170.9% |
| Q1 FY2021 | Mar 31, 2021 | $450.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $382.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $304.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $182.00K | – |
See a number that looks wrong?